Oral News and Research

RSS

Food preservative delivers one-two punch to cancer, antibiotic-resistant bacteria

Nisin, a naturally occurring food preservative that grows on dairy products, delivers a one-two punch to two of medicine's most lethal maladies: cancer and deadly, antibiotic-resistant bacteria.

12 Jan 2016

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

AbbVie, a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection.

12 Jan 2016

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

The most frequent fungal threat to humans, Candida albicans, is a common cause oral and genital infection. The fungal infections are often worsened by overwhelming inflammatory responses in the body and cause high mortality among risk groups. Umeå University doctoral student Ava Hosseinzadeh has discovered two novel anti-inflammatory agents, an antioxidant and an anti-inflammatory molecule, which could be used to control the hyper-inflammatory responses to the fungal infection.

12 Jan 2016

Blocking brain inflammation could protect against memory, behaviour changes

A University of Southampton-led study has found that blocking a receptor in the brain responsible for regulating immune cells could protect against the memory and behaviour changes seen in the progression of Alzheimer's disease.

11 Jan 2016

Global supply of oral cholera vaccines expected to double with new producer

The global supply of oral cholera vaccines is set to double after WHO approved a third producer, helping to address global shortages and expand access in more countries.

11 Jan 2016

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Rani Therapeutics announced today that it has entered into a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, to evaluate Rani's novel oral drug delivery platform. The companies have agreed to conduct feasibility studies over the next two years, in which Rani will test select biologic molecules in the area of metabolic disease to evaluate the oral delivery of these molecules.

6 Jan 2016

Use of oral fluconazole during pregnancy associated with increased risk of spontaneous abortion

In an analysis of approximately 1.4 million pregnancies in Denmark, use of the oral antifungal medication fluconazole during pregnancy was associated with an increased risk of spontaneous abortion compared with risk among unexposed women and women who used a topical antifungal during pregnancy, according to a study in the January 5 issue of JAMA.

6 Jan 2016

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

The Sohn Conference Foundation today announced a $50,000 grant to support funding of a Phase 2 cutting-edge pediatric clinical trial from the Neuroblastoma and Medulloblastoma Translational Research Consortium (NMTRC) now extending to New York City.

6 Jan 2016

New report raises questions about potential risks of chromium therapies

Chromium supplements are widely consumed for their antidiabetic activity as chromium(III) enhances the insulin sensitivity of cells. In particular, orthomolecular practitioners believe in the beneficial effects of providing the body with extra amounts of essential trace elements.

6 Jan 2016

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

Mylan N.V. today announced the U.S. launch of Norgestimate and Ethinyl Estradiol Tablets USP, 0.18 mg/0.025 mg, 0.215 mg/0.025 mg, and 0.25 mg/0.025 mg, which is the generic version of Janssen's Ortho Tri-Cyclen Lo Tablets.

5 Jan 2016

$New editorial calls on doctors to individualize treatment decisions based on patients' fracture risk$

New editorial calls on doctors to individualize treatment decisions based on patients' fracture risk

A new editorial published by an International Osteoporosis Foundation Working Group urges physicians to individualize treatment decisions based on their patients' fracture risk, rather than automatically interrupting or stopping bisphosphonate therapy after five or three years.

5 Jan 2016

Antiscarring paste can halt fibrosis caused by radiation treatment

An antiscarring paste when applied to the skin of mice halts fibrosis caused by the radiation used in cancer therapy. That is according to a study led by researchers at Laura and Isaac Perlmutter Cancer Center to be published tomorrow in the January edition of the Journal of the Federation of American Societies for Experimental Biology, or FASEB.

5 Jan 2016

High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

Research teams at Memorial Sloan Kettering Cancer Center and Epic Sciences have found that greater diversity among circulating tumor cells (CTCs) in the blood of advanced prostate cancer patients predicts not only shorter overall survival, but also the development of resistance to key anti-androgen therapies.

4 Jan 2016

New oral breast cancer drug has potential to combat other types of cancer

Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research conducted by experts at the Abramson Cancer Center in the University of Pennsylvania published this month in JAMA Oncology.

30 Dec 2015

Children at higher risk of developing cavities not getting needed preventive dental care

A landmark study of more than 97 million dental claims, conducted by Delta Dental Plans Association, found two-thirds of children who are at higher risk of developing cavities aren't getting recommended preventive dental care.

29 Dec 2015

E-cigarettes damage cells in ways that could lead to cancer

Adding to growing evidence on the possible health risks of electronic cigarettes, a lab team at the Veterans Affairs San Diego Healthcare System tested two products and found they damaged cells in ways that could lead to cancer. The damage occurred even with nicotine-free versions of the products.

29 Dec 2015

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

TWi Biotechnology Inc. today announced interim results from the ongoing Phase 2 proof of concept clinical study evaluating AC-201 CR as an oral uricosuric and anti-inflammatory agent for the treatment of hyperuricemia and prevention of gout flares combining with febuxostat, a xanthine oxidase inhibitor.

24 Dec 2015

Selexipag holds promise for treatment of pulmonary hypertension

Living with pulmonary arterial hypertension is challenging, but the chore of treating the rare heart disease may change following promising clinical trial data to be published in the Dec. 24 issue of the New England Journal of Medicine.

24 Dec 2015

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.

24 Dec 2015

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Cannabidiol (CBD), a medical marijuana derivative, was effective in reducing seizure frequency and well-tolerated and safe for most children and young adults enrolled in a year-long study led by epilepsy specialists at NYU Langone Medical Center.

24 Dec 2015

Oral News and Research

Food preservative delivers one-two punch to cancer, antibiotic-resistant bacteria

AbbVie begins six global Phase 3 clinical studies to evaluate efficacy of investigational HCV regimen

Novel anti-inflammatory agents could control hyper-inflammatory responses to fungal infection

Blocking brain inflammation could protect against memory, behaviour changes

Global supply of oral cholera vaccines expected to double with new producer

Rani Therapeutics, MedImmune collaborate to evaluate novel oral drug delivery platform

Use of oral fluconazole during pregnancy associated with increased risk of spontaneous abortion

Sohn Conference Foundation awards $50,000 grant to support cutting-edge pediatric clinical trial in New York

New report raises questions about potential risks of chromium therapies

Mylan announces U.S. launch of generic Ortho Tri-Cyclen Lo Tablets

New editorial calls on doctors to individualize treatment decisions based on patients' fracture risk

Antiscarring paste can halt fibrosis caused by radiation treatment

High diversity among circulating tumor cells predicts survival, treatment resistance in prostate cancer patients

New oral breast cancer drug has potential to combat other types of cancer

Children at higher risk of developing cavities not getting needed preventive dental care

E-cigarettes damage cells in ways that could lead to cancer

Positive interim results from TWIB's AC-201 CR Phase 2 study for hyperuricemia and gout

Selexipag holds promise for treatment of pulmonary hypertension

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Encouraging results from cannabidiol trial for treatment-resistant epilepsy

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News